Xilio Therapeutics (XLO) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on developing masked immuno-oncology therapies to improve cancer outcomes while minimizing systemic side effects.

• Utilizes a clinically-validated masking technology to selectively activate therapies within the tumor microenvironment.

• Advancing multiple preclinical and clinical programs, including masked multi-specifics, and has established strategic partnerships.

Financial performance and metrics

• As of May 11, 2026, public float was approximately $51.7 million, based on 5,982,839 outstanding shares and a price of $8.69 per share.

• Net tangible book value as of March 31, 2026, was $72.5 million ($12.55 per share); pro forma as adjusted after offering would be $88.8 million ($4.17 per share).

• Immediate dilution to new investors in the offering is estimated at $3.56 per share.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including R&D, clinical trials, acquisitions, development and commercial capabilities, personnel, collaborations, working capital, and capital expenditures.

• Proceeds may be temporarily invested in short-term, investment-grade instruments or U.S. government securities.

• Management has broad discretion over allocation of proceeds.